酪氨酸激酶抑制剂对QT间期的影响及临床意义研究进展

摘要/Abstract

摘要：

酪氨酸激酶抑制剂（tyrosine kinase inhibitors,TKIs）是一种新型的抗肿瘤药物，近年来被广泛应用于临床，已有药物临床试验表明该类药物对多种癌症有良好的治疗效果，其对QT间期影响也被大量报道，但每种药物对QT间期的影响程度不尽相同，因此，每种TKI药物在使用时需要注意及监测的指标也不尽相同。其中一些能引起严重QT间期延长甚至猝死的TKI，我们更需要根据患者的QT间期及时调整药物剂量。本文通过阅读国内外关于药物临床试验的相关文献及FDA药物说明书等，对目前已上市的TKI的临床药物研究中针对QT间期的实验以及用药中的剂量调整等需要注意的事项进行总结分析，通过对既往实验结果的总结，更好地了解对该类药物的作用风险，对临床用药起到一定的指导作用。

关键词: QT间期延长, 酪氨酸激酶抑制剂, 心率校正的QT间期（QTc）, 药物安全

Abstract:

Tyrosine kinase inhibitors (TKIs) are typically used as novel anti-tumor drugs, which have been widely applied to clinical treatments in recent years. Clinical trials have demonstrated that these drugs are effective in the treatment of various cancers. TKIs have also been reported to affect the QT interval, but the effects are not the same in different drug treatments. Therefore, each TKI has different warnings,precautions, and monitoring indicator. Some of TKIs can cause severe QT interval prolongation and even sudden death, so we need to adjust the dose according to the individual patient's QT interval. In this paper, we reviewed the related literature and the FDA drug instructions, and analyzed the clinical trials focusing the effects of listed TKIs on QT interval and dosage adjustment. The risks of such drugs have been better understood via the summary of the previous experimental results, and it would play a guiding role to TKIs clinical treatments.

Key words: interval prolong, tyrosine kinase inhibitors, heart rate corrected QT interval, drug safety

中图分类号:

袁点，余果，王大新. 酪氨酸激酶抑制剂对QT间期的影响及临床意义研究进展[J]. 中国临床药理学与治疗学, 2017, 22(7): 825-830.

YUAN Dian, YU Guo, WANG Daxin. Advances in effects of tyrosine kinase inhibitors on QT interval and its clinical significance[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 825-830.

参考文献

［1］Ederhy SL, Cohen A, Dufaitre G, et al. QT interval prolongation among patients treated with angiogenesis inhibitors［J］. J Target Oncol, 2009, 4(2): 89-99.
［2］Simon WR, Justin CH, Darby JS, et al. Detailed analysis of the impact of age on the QT interval［J］. J Geriatric Cardiol, 2016, 13(9): 740-748.
［3］Van RW, Van GT, Mathijssen RH, et al. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective ［J］. J Lancet Oncol, 2014, 15: e315-e326.
［4］Zeltser D, Justo D, Halkin A, et al. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable riskfactors［J］. J Medicine (Baltimore), 2003, 82(4): 282-290.
［5］Food and Drug Administration. Axitinib: indications and usage, clinical pharmacology［EB/OL］ .［2014-08-01］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202324s002lbl.pdf.
［6］Sonnichsen D, Dorer DJ, Cortes J, et al. Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies［J］. J Cancer Chemother Pharmacol, 2013, 71(6): 1599-1607.
［7］Food and Drug Administration. Ponatinib: indications and usage, clinical pharmacology ［EB/OL］.［2016-11-28］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203469s022lbl.pdf.
［8］Food and Drug Administration. Afatinib: indications and usage,clinical pharmacology ［EB/OL］.［2016-10-04］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201292s010lbl.pdf.
［9］Food and Drug Administration. Bosutinib: indications and usage,clinical pharmacology, clinical trials experience ［EB/OL］.［2016-11-17］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203341s006lbl.pdf.
［10］Abbas R, Hug BA, Leister C, et al. A randomized crossover, placebo-and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects ［J］. J Int J Cancer, 2012, 131(3): E304-E311.
［11］Food and Drug Administration. Cabozantinib: indications and usage, cardiac electrophysiology［EB/OL］.［2016-05-20］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203756s002lbl.pdf.
［12］Food and Drug Administration. Regorafenib: indications and usage,pharmacodynamics［EB/OL］.［2016-08-26］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203085s006lbl.pdf.
［13］Food and Drug Administration. Ruxolitinib: indications and usage, clinical pharmacology ［EB/OL］.［2016-03-10］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202192s012lbl.pdf.
［14］Punwani N, Yeleswaram S, Chen X, et al. Evaluation of the effect of ruxolitinib on cardiac repolarization: a thorough QT study ［J］. J Clin Pharmacol Drug Dev, 2014, 3(3): 207-214.
［15］Food and Drug Administration. Sorafenib: indications and usage, warnings and precautions, clinical pharmacology［EB/OL］.［2013-11-22］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021923s016lbl.pdf.
［16］Food and Drug Administration. Lapatinib: indications and usage, warnings and precautions, clinical pharmacology［EB/OL］.［2015-03-31］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/022059s020lbl.pdf.
［17］Food and Drug Administration. Cobimetinib: indications and usage,pharmacodynamics ［EB/OL］.［2016-05-31］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206192s001lbl.pdf.
［18］Food and Drug Administration. Ceritinib: indications and usage and warnings and precautions clinical pharmacology［EB/OL］.［2016-09-07］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205755s006lbl.pdf.
［19］Food and Drug Administration. Dasatinib: indications and usage, warnings and precautions, clinical trials experience, pharmacodynamics［EB/OL］.［2016-09-27］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021986s018lbl.pdf.
［20］Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors ［J］. J Cancer, 2010, 116(6): 1582-1591.
［21］Food and Drug Administration. Osimertinib: indications and usage, dose modifications, warnings and precautions ［EB/OL］.［2016-09-28］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208065s003lbl.pdf.
［22］Food and Drug Administration. Nilotinib: indications and usage, dosage and administration, contraindications, warnings and precautions, drug interactions, hepatic impairment, adverse reactions, drug interactions, pharmacokinetics ［EB/OL］.［2017-02-21］. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022068s024lbl.pdf.
［23］Food and Drug Administration. Crizotinib: indications and usage and dose modification and warnings and precautions and clinical trials experience and pharmacodynamics ［EB/OL］.［2017-01-24］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202570s020lbl.pdf.
［24］Food and Drug Administration. Lenvatinib: indications and usage, warnings and precautions, dose modifications, clinical trials experience, pharmacodynamics ［EB/OL］.［2016-05-13］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206947s003lbl.pdf.
［25］Shumaker RC, Zhou M, Ren M, et al. Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers ［J］. J Cancer Chemother Pharmacol, 2014, 73(6): 1109-1117.
［26］Food and Drug Administration. Pazopanib: indications and usage, warnings and precautions, pharmacodynamics［EB/OL］.［2016-08-05］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022465s023lbl.pdf.
［27］Heath EI, Infante J, Lewis LD, et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors ［J］. J Cancer Chemother Pharmacol, 2013, 71(3): 565-573.
［28］Food and Drug Administration. Sunitinib: indications and usage, warnings and precautions, clinical pharmacology［EB/OL］.［2015-11-16］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021938s031lbl.pdf.
［29］Bello CL, Mulay M, Huang X, et al. Electrocardiographic characterization of the QTc interval in patients with advanced solid tumors: pharmacokinetic-pharmacodynamic evaluation of sunitinib ［J］. J Clin Cancer Res, 2009, 15(22): 745-752.
［30］Food and Drug Administration. Trametinib: indications and usage, adverse reactions ［EB/OL］.［2017-02-24］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204114s006lbl.pdf.
［31］Flaherty L, Hamid O, Linette G, et al. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the united states ［J］. J Cancer J, 2014, 20(1): 18-24.
［32］Food and Drug Administration. Vemurafenib: indications and usage, dose modifications, warnings and precautions, clinical pharmacology ［EB/OL］.［2016-08-31］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202429s009lbl.pdf.
［33］Food and Drug Administration. Vandetanib: indications and usage, dosage and administration, contraindications, warnings and precautions, clinical studies experience, drug interactions, clinical pharmacology, pharmacokinetics ［EB/OL］.［2016-07-28］.https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022405s010lbl.pdf

[1]	张可心, 贾文静, 崔佳文, 敖路遥, 周芳, 王广基, 刘嘉莉. 第三代EGFR酪氨酸激酶抑制剂在非小细胞肺癌临床治疗中的应用及研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1016-1030.
[2]	何雪茹, 付裕豪, 荀雪姣, 崔艳军, 董占军. 尿苷二磷酸葡醛酸转移酶介导的酪氨酸激酶抑制剂药物相互作用研究进展[J]. 中国临床药理学与治疗学, 2022, 27(8): 936-945.
[3]	娄安琦, 余俊先, 程子昭, 苏强. 布鲁顿氏酪氨酸激酶（BTK）抑制剂与难治性套细胞淋巴瘤[J]. 中国临床药理学与治疗学, 2021, 26(6): 680-686.
[4]	常青青，彭英，王广基，孙建国. 抗肝癌小分子酪氨酸激酶抑制剂的临床研究进展[J]. 中国临床药理学与治疗学, 2019, 24(8): 948-956.
[5]	王璐，郑昕，王维聪，赵洪云，马宇翔，张力，胡蓓，江骥. 艾维替尼在一组中国晚期非小细胞肺癌病人体内单多次给药代谢产物的药代动力学研究[J]. 中国临床药理学与治疗学, 2018, 23(10): 1147-1152.
[6]	何苗，范晶，王子卫，赵和照. 胃肠间质瘤临床诊治现状与进展[J]. 中国临床药理学与治疗学, 2017, 22(11): 1315-1320.
[7]	王丽萍, 王果, 周宏灏. 表皮生长因子受体多态性对酪氨酸激酶抑制剂药效学影响的研究进展[J]. 中国临床药理学与治疗学, 2010, 15(8): 938-944.
[8]	谢海棠, Barton Cobert, 孙瑞元. “药品安全登记”—它确实有用吗?[J]. 中国临床药理学与治疗学, 2009, 14(1): 1-4.
[9]	李哲, 袁守军. 表皮生长因子受体酪氨酸激酶抑制剂在肿瘤治疗中的应用[J]. 中国临床药理学与治疗学, 2004, 9(4): 361-364.